<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557813</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-040444</org_study_id>
    <nct_id>NCT04557813</nct_id>
  </id_info>
  <brief_title>Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK-Fusion</brief_title>
  <acronym>REALTRK</acronym>
  <official_title>Registry for Molecular Testing, Treatment and Outcome of Patients With Locally Advanced or Metastatic Solid Tumors Harboring a Fusion of NTRK1, NTRK2 or NTRK3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this registry is to analyze treatment reality and outcome of patients with&#xD;
      locally advanced or metastatic solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The REALTRK registry will provide data on treatment reality of patients with locally advanced&#xD;
      or metastatic solid tumors harboring NTRK1, NTRK2 or NTRK3 gene fusions, thereby generating&#xD;
      real world evidence. It will identify factors that influence treatment decisions after&#xD;
      receiving the diagnosis of a NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive&#xD;
      cancer. All treatment lines administered before and after the molecular diagnosis of a NTRK&#xD;
      fusion-positive cancer, irrespective of the type of antineoplastic treatment, will be&#xD;
      documented. Data will be assessed at least 36 months per patient (i.e. until 36 months after&#xD;
      inclusion of the last patient in the study). This approach will allow a description of TRK&#xD;
      fusion protein-targeted therapies and other therapy strategies regarding effectiveness and&#xD;
      disease-related symptomology within the limitations of non-randomized studies in terms of&#xD;
      comparative analyses. Intra-individual and inter-individual comparisons (for the latter,&#xD;
      provided that a sufficient number of patients with a NTRK fusion-positive cancer are not&#xD;
      treated with a TRK inhibitor) could be performed.&#xD;
&#xD;
      The associated biomarker profiling module of the REALTRK registry will aim to set up a&#xD;
      decentralized biobank for future research on molecular alterations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">October 25, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>36 months</time_frame>
    <description>Proportion of patients with CR or PR as best response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and disease characteristics</measure>
    <time_frame>36 months</time_frame>
    <description>Descriptive summary of demographics, patient and disease characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test methods used for diagnosis of a NTRK fusion-positive cancer</measure>
    <time_frame>Day 1</time_frame>
    <description>Description of test methods used for diagnosis of a NTRK fusion-positive cancer and results thereof</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician-reported factors affecting decision to test for NTRK fusion and treatment decision</measure>
    <time_frame>Day 1</time_frame>
    <description>Description of physician-reported factors affecting decision to test for NTRK fusion and treatment decision making after diagnosis of NTRK gene fusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment reality after diagnosis of NTRK gene fusion</measure>
    <time_frame>36 months</time_frame>
    <description>Description of all treatment lines given to the patient after diagnosis of NTRK gene fusion including: Type of treatment (Systemic TRK inhibitor treatments or Non-TRK inhibitor treatments), treatment duration, dosing, treatment modifications and reasons thereof, reasons for end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of TRK inhibitor treatments</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment-emergent AEs (i.e., AEs which occurred during a specific TRK inhibitor treatment and in the respective survival FU) will be calculated per patient (absolute and relative frequencies) and case-based (absolute frequencies). The occurrence of any (S)AE will be displayed overall and per CTCAE grade. Adverse drug reactions (ADRs) and AESIs will be displayed accordingly.&#xD;
Incidence of AEs (MedDRA Preferred Term (PT) by System Organ Class (SOC)) will be calculated accordingly for each type of AE/ADR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician-reported evaluation of TRK inhibitor therapy</measure>
    <time_frame>Day 1</time_frame>
    <description>Description of physician-reported evaluation of TRK inhibitor therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-related symptoms</measure>
    <time_frame>36 months</time_frame>
    <description>Description of courses of disease-related symptoms (weight loss, ECOG) after diagnosis of NTRK gene fusion (Only for patients of inclusion group I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>36 months</time_frame>
    <description>Proportion of patients with CR, PR or SD as best response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>36 months</time_frame>
    <description>Time from start of treatment to the first objective tumor response (e.g., tumor shrinkage of â‰¥30%) observed for patients who achieved a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>36 months</time_frame>
    <description>Time from documentation of tumor response to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>36 months</time_frame>
    <description>Time from start of treatment until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Time from start of treatment until death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS ratio</measure>
    <time_frame>36 months</time_frame>
    <description>ratio of PFS of the first treatment line with a TRK inhibitor to time to progression (TTP) in the preceding treatment line without a TRK inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>36 months</time_frame>
    <description>Time from start of treatment until PD or death</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>NTRK Family Gene Mutation</condition>
  <arm_group>
    <arm_group_label>IC before start of any treatment</arm_group_label>
    <description>Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC after start of any treatment</arm_group_label>
    <description>IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deceased patients</arm_group_label>
    <description>Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with advanced (locally advanced or metastatic) solid tumors harboring a&#xD;
        NTRK1, NTRK2 or NTRK3 gene fusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with locally advanced or metastatic solid tumor with a documented NTRK gene&#xD;
             fusion&#xD;
&#xD;
          -  Criteria according to the current SmPCs of the used TRK inhibitors&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Signed and dated informed consent form (ICF) (only if patient is alive at time of data&#xD;
             entry into the project; not applicable for inclusion of deceased patients' data)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with a TRK inhibitor prior to Sept 19th, 2019&#xD;
&#xD;
          -  Participation in a clinical trial at enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Kasenda, PD Dr. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>iOMEDICO AG, Ellen-Gottlieb-Str. 19, 79106 Freiburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Niemeier, Dr.</last_name>
    <phone>+49/76115242</phone>
    <phone_ext>0</phone_ext>
    <email>realtrk@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis KurfÃ¼rstendamm</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingo Schwaner, MD</last_name>
      <email>ingo.schwaner@onkologie-kurfuerstendamm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis fÃ¼r interdisziplinÃ¤re Onkologie &amp; HÃ¤matologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Zaiss, MD</last_name>
      <email>info@onkologie-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hannover</city>
        <zip>30161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eyck von der Heyde, MD</last_name>
      <email>info@onkologie-am-raschplatz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum Ambulante Onkologie</name>
      <address>
        <city>Schorndorf</city>
        <zip>73614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter BÃ¼rkle, MD</last_name>
      <email>buerkle@onkologie-rems-murr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Kloster Paradiese GbR</name>
      <address>
        <city>Soest</city>
        <zip>59494</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Wortmann, MD</last_name>
      <email>dr.wortmann@onkologie-soest.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NTRK</keyword>
  <keyword>NTRK-fusion</keyword>
  <keyword>Neurotrophic Tyrosine Receptor Kinase</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

